LPI (LP Information)' newest research report, the “Chronic Heart Failure (CHF) Drugs Industry Forecast” looks at past sales and reviews total world Chronic Heart Failure (CHF) Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Chronic Heart Failure (CHF) Drugs sales for 2023 through 2029. With Chronic Heart Failure (CHF) Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chronic Heart Failure (CHF) Drugs industry.
This Insight Report provides a comprehensive analysis of the global Chronic Heart Failure (CHF) Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Chronic Heart Failure (CHF) Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Chronic Heart Failure (CHF) Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chronic Heart Failure (CHF) Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chronic Heart Failure (CHF) Drugs.
The global Chronic Heart Failure (CHF) Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Chronic Heart Failure (CHF) Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Chronic Heart Failure (CHF) Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Chronic Heart Failure (CHF) Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Chronic Heart Failure (CHF) Drugs players cover Abbott, Johnson & Johnson, Merck, Stanley Pharmaceuticals, New Haven Pharmaceuticals, Inc., Pfizer, GlaxoSmithKline plc, Novartis International AG and Biovail Corporation, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Chronic Heart Failure (CHF) Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Anti-clotting (Aspirin)
Antiplatelet Medicines (Clopidogrel, Prasugrel, and Ticagrelor)
Anticoagulant Medicines (Warfarin)
Blood Pressure Maintaining Agents (Angiotensin Converting Enzyme (ACE) Inhibitors)
Angiotensin II Receptor Blockers (ARB)
Statins
Diuretics
Nitrates
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott
Johnson & Johnson
Merck
Stanley Pharmaceuticals
New Haven Pharmaceuticals, Inc.
Pfizer
GlaxoSmithKline plc
Novartis International AG
Biovail Corporation
Bristol-Myers Squibb Company
Symplmed Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Chronic Heart Failure (CHF) Drugs market?
What factors are driving Chronic Heart Failure (CHF) Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Chronic Heart Failure (CHF) Drugs market opportunities vary by end market size?
How does Chronic Heart Failure (CHF) Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Chronic Heart Failure (CHF) Drugs Annual Sales 2018-2029 2.1.2 World Current & Future Analysis for Chronic Heart Failure (CHF) Drugs by Geographic Region, 2018, 2022 & 2029 2.1.3 World Current & Future Analysis for Chronic Heart Failure (CHF) Drugs by Country/Region, 2018, 2022 & 2029 2.2 Chronic Heart Failure (CHF) Drugs Segment by Type 2.2.1 Anti-clotting (Aspirin) 2.2.2 Antiplatelet Medicines (Clopidogrel, Prasugrel, and Ticagrelor) 2.2.3 Anticoagulant Medicines (Warfarin) 2.2.4 Blood Pressure Maintaining Agents (Angiotensin Converting Enzyme (ACE) Inhibitors) 2.2.5 Angiotensin II Receptor Blockers (ARB) 2.2.6 Statins 2.2.7 Diuretics 2.2.8 Nitrates 2.3 Chronic Heart Failure (CHF) Drugs Sales by Type 2.3.1 Global Chronic Heart Failure (CHF) Drugs Sales Market Share by Type (2018-2023) 2.3.2 Global Chronic Heart Failure (CHF) Drugs Revenue and Market Share by Type (2018-2023) 2.3.3 Global Chronic Heart Failure (CHF) Drugs Sale Price by Type (2018-2023) 2.4 Chronic Heart Failure (CHF) Drugs Segment by Application 2.4.1 Hospital 2.4.2 Clinic 2.4.3 Others 2.5 Chronic Heart Failure (CHF) Drugs Sales by Application 2.5.1 Global Chronic Heart Failure (CHF) Drugs Sale Market Share by Application (2018-2023) 2.5.2 Global Chronic Heart Failure (CHF) Drugs Revenue and Market Share by Application (2018-2023) 2.5.3 Global Chronic Heart Failure (CHF) Drugs Sale Price by Application (2018-2023) 3 Global Chronic Heart Failure (CHF) Drugs by Company 3.1 Global Chronic Heart Failure (CHF) Drugs Breakdown Data by Company 3.1.1 Global Chronic Heart Failure (CHF) Drugs Annual Sales by Company (2018-2023) 3.1.2 Global Chronic Heart Failure (CHF) Drugs Sales Market Share by Company (2018-2023) 3.2 Global Chronic Heart Failure (CHF) Drugs Annual Revenue by Company (2018-2023) 3.2.1 Global Chronic Heart Failure (CHF) Drugs Revenue by Company (2018-2023) 3.2.2 Global Chronic Heart Failure (CHF) Drugs Revenue Market Share by Company (2018-2023) 3.3 Global Chronic Heart Failure (CHF) Drugs Sale Price by Company 3.4 Key Manufacturers Chronic Heart Failure (CHF) Drugs Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Chronic Heart Failure (CHF) Drugs Product Location Distribution 3.4.2 Players Chronic Heart Failure (CHF) Drugs Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023) 3.6 New Products and Potential Entrants 3.7 Mergers & Acquisitions, Expansion 4 World Historic Review for Chronic Heart Failure (CHF) Drugs by Geographic Region 4.1 World Historic Chronic Heart Failure (CHF) Drugs Market Size by Geographic Region (2018-2023) 4.1.1 Global Chronic Heart Failure (CHF) Drugs Annual Sales by Geographic Region (2018-2023) 4.1.2 Global Chronic Heart Failure (CHF) Drugs Annual Revenue by Geographic Region (2018-2023) 4.2 World Historic Chronic Heart Failure (CHF) Drugs Market Size by Country/Region (2018-2023) 4.2.1 Global Chronic Heart Failure (CHF) Drugs Annual Sales by Country/Region (2018-2023) 4.2.2 Global Chronic Heart Failure (CHF) Drugs Annual Revenue by Country/Region (2018-2023) 4.3 Americas Chronic Heart Failure (CHF) Drugs Sales Growth 4.4 APAC Chronic Heart Failure (CHF) Drugs Sales Growth 4.5 Europe Chronic Heart Failure (CHF) Drugs Sales Growth 4.6 Middle East & Africa Chronic Heart Failure (CHF) Drugs Sales Growth 5 Americas 5.1 Americas Chronic Heart Failure (CHF) Drugs Sales by Country 5.1.1 Americas Chronic Heart Failure (CHF) Drugs Sales by Country (2018-2023) 5.1.2 Americas Chronic Heart Failure (CHF) Drugs Revenue by Country (2018-2023) 5.2 Americas Chronic Heart Failure (CHF) Drugs Sales by Type 5.3 Americas Chronic Heart Failure (CHF) Drugs Sales by Application 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Chronic Heart Failure (CHF) Drugs Sales by Region 6.1.1 APAC Chronic Heart Failure (CHF) Drugs Sales by Region (2018-2023) 6.1.2 APAC Chronic Heart Failure (CHF) Drugs Revenue by Region (2018-2023) 6.2 APAC Chronic Heart Failure (CHF) Drugs Sales by Type 6.3 APAC Chronic Heart Failure (CHF) Drugs Sales by Application 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Chronic Heart Failure (CHF) Drugs by Country 7.1.1 Europe Chronic Heart Failure (CHF) Drugs Sales by Country (2018-2023) 7.1.2 Europe Chronic Heart Failure (CHF) Drugs Revenue by Country (2018-2023) 7.2 Europe Chronic Heart Failure (CHF) Drugs Sales by Type 7.3 Europe Chronic Heart Failure (CHF) Drugs Sales by Application 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Chronic Heart Failure (CHF) Drugs by Country 8.1.1 Middle East & Africa Chronic Heart Failure (CHF) Drugs Sales by Country (2018-2023) 8.1.2 Middle East & Africa Chronic Heart Failure (CHF) Drugs Revenue by Country (2018-2023) 8.2 Middle East & Africa Chronic Heart Failure (CHF) Drugs Sales by Type 8.3 Middle East & Africa Chronic Heart Failure (CHF) Drugs Sales by Application 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Chronic Heart Failure (CHF) Drugs 10.3 Manufacturing Process Analysis of Chronic Heart Failure (CHF) Drugs 10.4 Industry Chain Structure of Chronic Heart Failure (CHF) Drugs 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Chronic Heart Failure (CHF) Drugs Distributors 11.3 Chronic Heart Failure (CHF) Drugs Customer 12 World Forecast Review for Chronic Heart Failure (CHF) Drugs by Geographic Region 12.1 Global Chronic Heart Failure (CHF) Drugs Market Size Forecast by Region 12.1.1 Global Chronic Heart Failure (CHF) Drugs Forecast by Region (2024-2029) 12.1.2 Global Chronic Heart Failure (CHF) Drugs Annual Revenue Forecast by Region (2024-2029) 12.2 Americas Forecast by Country 12.3 APAC Forecast by Region 12.4 Europe Forecast by Country 12.5 Middle East & Africa Forecast by Country 12.6 Global Chronic Heart Failure (CHF) Drugs Forecast by Type 12.7 Global Chronic Heart Failure (CHF) Drugs Forecast by Application 13 Key Players Analysis 13.1 Abbott 13.1.1 Abbott Company Information 13.1.2 Abbott Chronic Heart Failure (CHF) Drugs Product Portfolios and Specifications 13.1.3 Abbott Chronic Heart Failure (CHF) Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.1.4 Abbott Main Business Overview 13.1.5 Abbott Latest Developments 13.2 Johnson & Johnson 13.2.1 Johnson & Johnson Company Information 13.2.2 Johnson & Johnson Chronic Heart Failure (CHF) Drugs Product Portfolios and Specifications 13.2.3 Johnson & Johnson Chronic Heart Failure (CHF) Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.2.4 Johnson & Johnson Main Business Overview 13.2.5 Johnson & Johnson Latest Developments 13.3 Merck 13.3.1 Merck Company Information 13.3.2 Merck Chronic Heart Failure (CHF) Drugs Product Portfolios and Specifications 13.3.3 Merck Chronic Heart Failure (CHF) Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.3.4 Merck Main Business Overview 13.3.5 Merck Latest Developments 13.4 Stanley Pharmaceuticals 13.4.1 Stanley Pharmaceuticals Company Information 13.4.2 Stanley Pharmaceuticals Chronic Heart Failure (CHF) Drugs Product Portfolios and Specifications 13.4.3 Stanley Pharmaceuticals Chronic Heart Failure (CHF) Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.4.4 Stanley Pharmaceuticals Main Business Overview 13.4.5 Stanley Pharmaceuticals Latest Developments 13.5 New Haven Pharmaceuticals, Inc. 13.5.1 New Haven Pharmaceuticals, Inc. Company Information 13.5.2 New Haven Pharmaceuticals, Inc. Chronic Heart Failure (CHF) Drugs Product Portfolios and Specifications 13.5.3 New Haven Pharmaceuticals, Inc. Chronic Heart Failure (CHF) Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.5.4 New Haven Pharmaceuticals, Inc. Main Business Overview 13.5.5 New Haven Pharmaceuticals, Inc. Latest Developments 13.6 Pfizer 13.6.1 Pfizer Company Information 13.6.2 Pfizer Chronic Heart Failure (CHF) Drugs Product Portfolios and Specifications 13.6.3 Pfizer Chronic Heart Failure (CHF) Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.6.4 Pfizer Main Business Overview 13.6.5 Pfizer Latest Developments 13.7 GlaxoSmithKline plc 13.7.1 GlaxoSmithKline plc Company Information 13.7.2 GlaxoSmithKline plc Chronic Heart Failure (CHF) Drugs Product Portfolios and Specifications 13.7.3 GlaxoSmithKline plc Chronic Heart Failure (CHF) Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.7.4 GlaxoSmithKline plc Main Business Overview 13.7.5 GlaxoSmithKline plc Latest Developments 13.8 Novartis International AG 13.8.1 Novartis International AG Company Information 13.8.2 Novartis International AG Chronic Heart Failure (CHF) Drugs Product Portfolios and Specifications 13.8.3 Novartis International AG Chronic Heart Failure (CHF) Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.8.4 Novartis International AG Main Business Overview 13.8.5 Novartis International AG Latest Developments 13.9 Biovail Corporation 13.9.1 Biovail Corporation Company Information 13.9.2 Biovail Corporation Chronic Heart Failure (CHF) Drugs Product Portfolios and Specifications 13.9.3 Biovail Corporation Chronic Heart Failure (CHF) Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.9.4 Biovail Corporation Main Business Overview 13.9.5 Biovail Corporation Latest Developments 13.10 Bristol-Myers Squibb Company 13.10.1 Bristol-Myers Squibb Company Company Information 13.10.2 Bristol-Myers Squibb Company Chronic Heart Failure (CHF) Drugs Product Portfolios and Specifications 13.10.3 Bristol-Myers Squibb Company Chronic Heart Failure (CHF) Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.10.4 Bristol-Myers Squibb Company Main Business Overview 13.10.5 Bristol-Myers Squibb Company Latest Developments 13.11 Symplmed Pharmaceuticals 13.11.1 Symplmed Pharmaceuticals Company Information 13.11.2 Symplmed Pharmaceuticals Chronic Heart Failure (CHF) Drugs Product Portfolios and Specifications 13.11.3 Symplmed Pharmaceuticals Chronic Heart Failure (CHF) Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.11.4 Symplmed Pharmaceuticals Main Business Overview 13.11.5 Symplmed Pharmaceuticals Latest Developments 14 Research Findings and Conclusion